Richard A. Slayden
Assistant Professor

Office: 491-2902
Lab: 491-1925 Fax: 491-1815
Email: Richard.Slayden@colostate.edu
Office: B208 Microbiology Building
Lab: B203 Microbiology Building

 

Degrees

• B.S., Colorado State University
• Ph.D., Colorado State University

Research Interests

Bacterial population differentiation and drug discovery

• Our major research emphasis is the study of bacterial differentiation into distinct cellular populations. The premise is that although bacteria are genetically clonal they are phenotypically differentiated. The benefit to the bacteria is optimization of population survival by differentiation into distinct cell types. These cell type may include; (1) actively growing cells, (2) metabolically dormant, (3) hyper-mutable and (4) altruistically suicidal. The presence of these four phenotypically activated populations would allow the bacterial population the adaptation characteristics required to actively infect and evade host defenses.
• In addition a major effort in the laboratory is the development of novel post-genomic technologies.
• We are prominent in these research areas. With other faculty we work together as a group - The Mycobacteria Research Laboratories.

Manuscripts

• Groathouse et al (2006) J Clinical Microbiology, Table S1 Full Data Set.
• Huang et al (2006) J Med Chem.
• Slayden et al (2006) Microbiology, Table S1, Table S2, Table S3.

Selected Publications

Pub Med for Slayden RA.

• G. S. Besra, T. Sievert, R. E. Lee, R. A. Slayden, P. J. Brennan, K. Takayama (1994) Identification of the Apparent Carrier in Mycolic Acid Synthesis. Proceeding in the National Academy of Sciences, USA 91:12735-39.
• K. Mikosova, R. A. Slayden, G. S. Besra, P. J. Brennan (1995) Biogenesis of the Mycobacterial Cell Wall and the Site of Action of Ethambutol. Antimicrobial Agents and Chemotherapy 39(11):2484-89.
• R. A. Slayden, R. E. Lee, J. W. Armour, A. M. Cooper, I. A. Orme, P. J. Brennan, G. S. Besra (1996) Anti-Mycobacterial Action of Thiolactomycin: An Inhibitor of Fatty Acid and Mycolic Acid Synthesis. Antimicrobial Agents and Chemotherapy 40(12):2813-39.
• K. Mdluli, R. A. Slayden, Y. Zhu, S. Rhamaswamy, X. Pan, D. Mead, D. Crane, J. M. Musser, C. E. Barry 3rd (1998) Inhibition of a Mycobacteruim tuberculosis Keto-acyl ACP Synthase by Isoniazid. Science 280:1607-10.
• C. E. Barry, 3rd, R. E. Lee, K. Mdluli, A. Sampson, B. G. Schroeder, R. A. Slayden, Y. Yuan (1998) Mycolic Acids: Structure, Biosynthesis and Physiological Functions. Progress in Lipid Research 37(2/3):143-79.
• C. E. Barry, 3rd, R. A. Slayden, K. Mdluli (1998) Mechanisms of Isoniazid Resistance in Mycobacterium tuberculosis. Drug Resistance Updates 1:128-34.
• Richard A. Slayden, Richard E. Lee, Clifton E. Barry, 3rd (2000) Isoniazid Effects Multiple Components of the Type II Fatty Acid Synthase System of Mycobacterium tuberculosis. Molecular Microbiology 38(3):514-25.
• Marcel A. Behr, Benjamin G. Shroeder, Jacueline N. Brinkman, Richard A. Slayden, Clifton E. Barry, 3rd (2000) Point Mutation in mma3 gene is responsible for impaired methoxymycolic acid production in BCG strains obtained after 1927. Journal of Bacteriology 182:3394-9.
• Linda Wang, Richard A. Slayden, Clifton E. Barry, 3rd, Jun Liu (2000) Cell Wall Structure of a Mutant of Mycobacterium smegmatis Defective in the Biosynthesis of Mycolic Acids. Journal of Biological Chemistry 275(10):7224-9.
• Richard A. Slayden, Clifton E. Barry, 3rd (2000) Genetics of Isoniazid Resistance in Mycobacterium tuberculosis. Microbes and Infection 2(6):659-69.
• C. E. Barry, 3rd, R. A. Slayden, A. E. Sampson, R. E. Lee (2000) The use of Genomics and Combinatorial Chemistry in the Development of New Antimycobacterial Drugs. Biochemical Pharmacology 59:221-31.
• I. Rosenkrands, R. A. Slayden, Jane Crawford, C. Aagaard, C. E. Barry, 3rd, P. Andersen (2001) The Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. Journal of Bacteriology 183(13):3485-91.
• Richard A. Slayden and Clifton E. Barry, 3rd (2002) The role of KasA and KasB in the Biosynthesis of Meromycolic Acids in Mycobacterium tuberculosis and Isoniazid Resistance. Tuberculosis 82 (4/5):149-60.
• Richard Lee, Marina Protopopova, Emma Crooks, Richard A. Slayden, Clifton E. Barry 3rd (2003) Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. Journal of Combichem 5(2):172-87.
• Phetsuksiri B, Jackson M, Scherman H, McNeil M, Besra GS, Baulard AR, Slayden RA, DeBarber AE, Barry CE 3rd, Baird MS, Crick DC, Brennan PJ. (2003) Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J Biol Chem. 278(52): 53123-30.
• Huang, Q., Kirikae, F., Kirikae, T., Pepe, A., Amin, A., Respicio, L., Slayden, R. A., Tonge, P. J. Ojima, I. (2006) Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. J Med Chem. 49(2):463-6.
• Todd J. Sullivan, James J. Truglio, Melissa E. Boyne, Polina Novichenok, Xujie Zhang, Christopher F. Stratton, Huei-Jiun Li, Tejinder Kaur, Amol Amin, Francis Johnson, Richard A. Slayden, Caroline Kisker, Peter J. Tonge (2006) High Affinity InhA Inhibitors with Activity against Drug-Resistant Strains of Mycobacterium tuberculosis. ACS Chem. Biol. 1 (1), 43-53.
• Groathouse, N. A., Brown, S. E., Knudson, D. L., Brennan, P. J., Slayden, R. A. (2006) Isothermal amplification and molecular typing of the obligate intracellular pathogen Mycobacterium leprae isolated from tissues of unknown origin. J. Clin. Microbiol. 44(4):1502-8.
• Slayden, R. A., Knudson, D. L., Belisle, J. T. (2006) Identification of cell cycle regulators in Mycobacterium tuberculosis by inhibition of septum formation and global transcriptional analysis. Microbiology. 152:1789-97.
• Sartain, M. J., Slayden, R. A., Singh, K. K., Laal, S., Belisle, J. T. (2006) Disease state differentiation and identification of tuberculosis biomarkers via native antigen array profiling. Mol Cell Proteomics. 5(11):2102-2113.
• Groathouse, N. A., Amin, A., Marques, M. A., Spencer, J. S., Gelber, R., Knudson, D. L., Belisle, J. T., Brennan, P. J., Slayden, R. A. (2006) Use of protein microarrays to define the humoral immune response in leprosy patients and identification of disease-state-specific antigenic profiles. Infect. Immun. 74(11):6458-66.
• Peter J. Tonge, Caroline Kisker and Richard A. Slayden (2007) Development of Modern InhA Inhibitors to Combat Drug Resistant Strains of Mycobacterium tuberculosis. Current Topics in Medicinal Chemistry. 7(5):489-98.
• Qing huang, Peter J. Tonge, Richard A. Slayden Teruo Kirikae and Iwao Ojima. (2007) FtsZ: A Novel Target for Tuberculosis Drug Discovery. Current Topics in Medicinal Chemistry. 7(5):527-43.